Ceftolozane
- Generic Name
- Ceftolozane
- Brand Names
- Zerbaxa
- Drug Type
- Small Molecule
- Chemical Formula
- C23H30N12O8S2
- CAS Number
- 689293-68-3
- Unique Ingredient Identifier
- 37A4IES95Q
- Background
Ceftolozane is a semi-synthetic broad-spectrum fifth generation cephalosporin. It was approved by the FDA in 2014 for use in combination with Tazobactam for the treatment of serious infections, such as intra-abdominal infections and complicated urinary tract infections. The manufacturer of this drug is Cubist Pharmaceuticals. Most recently, in June 2019, ceftolozane-tazobactam was approved for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.
Hospital-acquired pneumonia and ventilator-associated pneumonia are major causes of morbidity and mortality in hospitalized patients and the use of ceftolozane-tazobactam offers effective activity against various organisms causing these infections, such as Pseudomonas aeruginosa.
- Indication
Ceftolozane is used in combination with tazobactam for the treatment of infections caused by designated susceptible microorganisms in adult and pediatric patients:
- Associated Conditions
- Nosocomial Pneumonia, Ventilator Associated Bacterial Pneumonia (VABP), Complicated Pyelonephritis, Complicated Urinary Tract Infection caused by susceptible bacteria, Complicated intra-abdominal bacterial infections
Ceftolozane-Tazobactam for Directed Treatment of Pseudomonas Aeruginosa Bacteremia and Pneumonia in Patients With Hematological Malignancies and Hematopoietic Stem Cell Transplantation
- Conditions
- Pseudomonas AeruginosaHematologic MalignancyPneumonia
- Interventions
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 20
- Registration Number
- NCT04673175
- Locations
- 🇺🇸
Weill Cornell Medicine, New York, New York, United States
Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam
- Conditions
- Other Infectious Diseases
- Interventions
- Other: Laboratory Biomarker Analysis
- First Posted Date
- 2018-04-03
- Last Posted Date
- 2022-03-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 100
- Registration Number
- NCT03485950
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Safety and Efficacy of IV CXA-101 and IV Ceftazidime in Patients With Complicated Urinary Tract Infections
- Conditions
- Complicated Urinary Tract Infection
- Interventions
- First Posted Date
- 2009-06-16
- Last Posted Date
- 2018-10-18
- Lead Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Target Recruit Count
- 129
- Registration Number
- NCT00921024
- Locations
- 🇵🇱
Szpital Bielański im.Ks. Jerzego Popiełuszki Samodzielny Publiczny Zakład Opieki Zdrowotnej IV Kliniczny Oddzial Chorób Wewnętrznych, Warszawa, Poland
🇵🇱Szpital Praski p.w. Przemienienia Pańskiego Samodzielny Publiczny Zakład Opieki Zdrowotnej ll Oddział Wewnętrznych, Warszawa, Poland
🇵🇱Samodzielny Publiczny Szpital Wojewódźki im. Papieża Jana Pawła ll Oddział Wewnętrznych Nefrologiczno-Endokrynologiczny ze Stacją Dializ, Zamość, Poland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.